Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine

Journal of Pediatric Hematology/Oncology

Volumn 18, Issue 1, 1996, Pages 42-45

  Styles, Lori A ^a   Vichinsky, Elliott P ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Desferrioxamine; Ototoxicity; Sickle cell disease; Thalassemia

Indexed keywords

DEFEROXAMINE;

ADOLESCENT; ADULT; ARTICLE; AUDIOGRAPHY; AUDITORY THRESHOLD; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; DRUG EFFECT; ERYTHROCYTE APLASIA; HEARING IMPAIRMENT; HEMOGLOBINOPATHY; HUMAN; OTOTOXICITY; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SUBCUTANEOUS DRUG ADMINISTRATION; THALASSEMIA;

ADOLESCENT; ADULT; AUDIOMETRY; AUDITORY THRESHOLD; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FERRITINS; HEARING; HEMOGLOBINOPATHIES; HUMANS; SIDEROPHORES;

EID: 0030071019     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199602000-00008     Document Type: Article

References (12)

1. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995;332:918-22.
2. Collins AF, Fasses FF, Stobie S, et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994;83:2329-33.
3. Porter JB, Huehns ER. The toxic effects of desferrioxamine. Baillieres Clin Haematol 1989;2:459-74.
4. Fosburg MT, Nathan DG. Treatment of Cooley's anemia. Blood 1990;76:435-44.
5. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986;314:869-73.
6. Porter JB, Jaswon MS, Heuhns ER, East CA, Hazell JWP. Desferrioxamine ototoxicity: evaluation of risk factors in thalassemic patients and guidelines for safe dosage. Br J Haematol 1989;73:403-9.
7. Argiolu F, Diana G, Avignone A, Cao A. Hearing impairment during deferoxamine therapy for thalassemia major [Letter]. J Pediatr 1991;118:826-7.
8. Albera R, Pia F, Morra B, et al. Hearing loss and desferrioxamine in homozygous beta-thalassemia. Audiology 1988;27:207-14.
9. Gallant T, Boyden M, Gallant LA, Carley H, Freedman MH. Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. Am J Med 1987;83:1085-90.
10. Cohen A, Martin M, Mizanin J, Konkle DF, Schwartz E. Vision and hearing during deferoxamine therapy. J Pediatr 1990;117:326-30.
11. American National Standards Institute. Specifications for audiometers. ANSI S36-1969. New York: American National Standards Institute, 1969.
12. Abbuhl S, Jacobson S, Murphy JG, Gibson G. Serum concentrations of meperidine in patients with sickle cell crisis. Ann Emerg Med 1986;15:433-8.